South African-based JSE Limited listed Aspen continues to increase the number of lives benefiting from its products, reaching more than 150 countries across the world. The extensive basket of Aspen products provides treatment for a broad spectrum of acute and chronic conditions experienced throughout all stages of life.
Aspen has an extensive global presence and is represented in 47 countries including South Africa, Australia, Hong Kong, Malaysia, Philippines, Taiwan, Japan, Kenya, Nigeria, Tanzania, Uganda, Ireland, United Arab Emirates, Germany, France, the Netherlands, Mauritius, Brazil, Mexico, Venezuela and the United States. Acquisitions announced in 2013 further extended the Group’s emerging market presence to the Commonwealth of Independent States (“CIS”), comprising Russia and the former Soviet Republics as well as to Central and Eastern Europe. The Group has 26 manufacturing facilities at 18 sites on 6 continents and approximately 10 000 employees.
Aspen Pharmacare, Africa's largest generic-drug maker, posted a 3.9 percent gain in full-year profit, as the expansion of its international business outweighed the rising cost of imported materials. CNBC Africa's David Williams spoke with CEO, Steven Saad for more.